Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial for Patients With Inflammatory (Stage IIIb) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue With 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF.

Next Previous
X
Search
Trial Profile

A Phase II Trial for Patients With Inflammatory (Stage IIIb) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue With 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan; Interleukin-2; Melphalan; Tamoxifen; Thiotepa
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Jul 2017 Biomarkers information updated
    • 23 Jun 2009 Actual end date (Nov 2003) added as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top